Pancreatic Cancer Research

ResearcherCleveland ClinicActive in the last 2 years

Howard P. Safran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6221-7147; OpenAlex author ID A5013039829, A5013270587. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 1, last author 1)
Trials
4 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
83
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: 1 trial · 2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 4 papers · 2012: 1 paper, 1 trial · 2013: 1 paper · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 18

  1. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  2. Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets. Co-author DOI 10.1016/j.mam.2026.101476↗
  3. Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. Co-author DOI 10.1200/po-26-00138↗
  4. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  5. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Co-author DOI 10.1080/15384047.2021.1976567↗
  6. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  7. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295). Last author DOI 10.1097/coc.0000000000000762↗
  8. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  9. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  10. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Co-author DOI 10.1016/j.ijrobp.2015.10.062↗
  11. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study. Co-author DOI 10.1097/coc.0000000000000246↗
  12. Optimizing initial chemotherapy for metastatic pancreatic cancer. First author DOI 10.2217/fon-2015-0006↗
  13. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Co-author DOI 10.1007/s11605-012-2064-6↗
  14. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic panc… Co-author DOI 10.1093/annonc/mds142↗
  15. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for panc… Co-author DOI 10.1016/j.ijrobp.2010.07.1993↗
  16. Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Co-author DOI 10.1097/coc.0b013e3181d26b01↗
  17. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correl… Co-author DOI 10.1200/jco.2010.33.8038↗
  18. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S… Co-author DOI 10.1245/s10434-011-1630-6↗

Trials 4

  1. BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study Principal investigator NCT01744353↗
  2. BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer Principal investigator NCT00447122↗
  3. A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema Principal investigator NCT00439179↗
  4. Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas Study chair NCT00003797↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wafik S. El‐Deiry · 2 shared papers, 2021–2026 · strength 0.39
  2. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  3. Xuewei Bai · 3 shared papers, 2019–2026 · strength 0.38
  4. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  5. Rui Kong · 3 shared papers, 2019–2026 · strength 0.38
  6. Katsuya Nagaoka · 3 shared papers, 2019–2026 · strength 0.38
  7. Xiaoqun Dong · 3 shared papers, 2019–2026 · strength 0.38
  8. Jack R. Wands · 3 shared papers, 2019–2026 · strength 0.38
  9. Kosuke Ogawa · 3 shared papers, 2019–2026 · strength 0.38
  10. Le Li · 3 shared papers, 2019–2026 · strength 0.38
  11. Alexander Grenander Raufi · 2 shared papers, 2020–2026 · strength 0.30
  12. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  13. William F. Regine · 5 shared papers, 2011–2021 · strength 0.29
  14. John Parker Hoffman · 5 shared papers, 2011–2021 · strength 0.29
  15. Ross Allen Abrams · 5 shared papers, 2011–2021 · strength 0.29
  16. Andrew Karam · 1 shared paper, 2026 · strength 0.26
  17. Divya Murthy · 1 shared paper, 2026 · strength 0.26
  18. Sendurai A. Mani · 1 shared paper, 2026 · strength 0.26
  19. Attila A. Seyhan · 1 shared paper, 2026 · strength 0.26
  20. Razelle Kurzrock · 1 shared paper, 2026 · strength 0.26
  21. Christopher H. Crane · 4 shared papers, 2011–2021 · strength 0.26
  22. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  23. Alina Cornelia Iuga · 1 shared paper, 2026 · strength 0.20
  24. Michael S. May · 1 shared paper, 2026 · strength 0.20
  25. Susan Elaine Bates · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.